Leo Pharma CEO: Acquisition strengthens our geographical reach
The USD 713.5 million (DKK 5 billion) acquisition, paid in cash, of Astellas Pharma’s dermatological portfolio sets the stage for additional growth. According to Gitte Aabo, CEO of Leo Pharma, the Danish pharmaceutical group is still on the lookout for further acquisitions.
BY BENJAMIN WERNER CHRISTENSEN
Even though Leo Pharma, with the acquisition of Astellas Pharma’s dermatological portfolio for a price of around USD 713.5 million, has performed its biggest acquisition ever, the company is far from done in the M&A market, says Leo Pharma CEO Gitte Aabo.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo Pharma in EUR 675 million acquisition
For abonnenter
Leo Pharma makes investment in Dutch company
For abonnenter
